Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
NCT ID: NCT05352893
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
45 participants
INTERVENTIONAL
2022-04-14
2023-08-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
NCT05366855
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
NCT03619902
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
NCT03633396
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
NCT03998683
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
NCT02978690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IV high dose Imsidolimab, other name ANB019
ANB019 Biological Humanized Monoclonal Antibody High Dose
Imsidolimab high dose
intravenous
IV low dose Imsidolimab, other name ANB019
ANB019 Biological Humanized Monoclonal Antibody Low Dose
Imsidolimab low dose
intravenous
IV Placebo
Placebo Solution
Placebo
intravenous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imsidolimab high dose
intravenous
Imsidolimab low dose
intravenous
Placebo
intravenous
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subject flare is so severe that patient's life is at risk
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 109
Largo, Florida, United States
Site 105
Louisville, Kentucky, United States
Site 101
Ann Arbor, Michigan, United States
Site 108
Dallas, Texas, United States
Site 102
Springville, Utah, United States
Site 35-101
Melbourne, , Australia
Site 35102
Sydney, , Australia
Site 59104
Batumi, , Georgia
Site 50103
Tbilisi, , Georgia
Site 59-101
Tbilisi, , Georgia
Site 59-105
Tbilisi, , Georgia
Site 59102
Tbilisi, , Georgia
Site 17102
Bensheim, , Germany
Site 17104
Bonn, , Germany
Site 17103
Hanau, , Germany
Site 17105
Würzburg, , Germany
Site 42104
Cheras, , Malaysia
Site 42106
Johor Bahru, , Malaysia
Site 42105
Kota Bharu, , Malaysia
Site 42101
Kuala Lumpur, , Malaysia
Site 42102
Muar town, , Malaysia
Site 42103
Putrajaya, , Malaysia
Site 64-102
Casablanca, , Morocco
Site 64-103
Casablanca, , Morocco
Site 64-101
Oujda, , Morocco
Site 30104
Krakow, , Poland
Site 30105
Lodz, , Poland
Site 30103
Ossy, , Poland
Site 30101
Rzeszów, , Poland
Site 30102
Wroclaw, , Poland
Site 31-102
Bucharest, , Romania
31-101
Cluj-Napoca, , Romania
Site 31-103
Iași, , Romania
Site 38-101
Svidník, , Slovakia
Site 45101
Pusan, , South Korea
Site 45102
Seoul, , South Korea
Site 45103
Seoul, , South Korea
Site 45104
Seoul, , South Korea
Site 24-101
Barcelona, , Spain
Site 24-104
Las Palmas de Gran Canaria, , Spain
Site 24-102
Madrid, , Spain
Site 24-103
Madrid, , Spain
Sie 24-105
Valencia, , Spain
Site 63101
Kaohsiung City, , Taiwan
Site 63102
Taipei, , Taiwan
Site 63103
Taipei, , Taiwan
Site 64104
Taipei, , Taiwan
Site 46101
Bangkok, , Thailand
Site 46102
Chiang Mai, , Thailand
Site 46104
Khon Kaen, , Thailand
Site 46103
Pathum Thani, , Thailand
Site 62-101
Sfax, , Tunisia
Site 62-102
Sousse, , Tunisia
Site 62-103
Tunis, , Tunisia
Site 33-102
Ankara, , Turkey (Türkiye)
Site 33-103
Antalya, , Turkey (Türkiye)
Site 33-105
Istanbul, , Turkey (Türkiye)
Site 33-106
Istanbul, , Turkey (Türkiye)
Site 33-107
Istanbul, , Turkey (Türkiye)
Site 33-104
Nilufer, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANB019-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.